Exploring how CDK1 affects cancer and potential treatments
Understanding CDK1 Function and Cancer Vulnerabilities
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11082306
This study is looking at a protein called CDK1 to see how it affects aggressive cancers and how blocking it might help improve cancer treatments, using special mouse models to learn more about how this could work while protecting healthy cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11082306 on ClinicalTrials.gov |
What this research studies
This research investigates the role of CDK1, a protein that regulates the cell cycle, in aggressive and metastatic cancers. The team aims to understand how cancer cells adapt to targeted therapies and how inhibiting CDK1 could lead to better treatment outcomes. By using engineered mouse models, they will explore the effects of CDK1 inhibition on cancer cell behavior and its potential to induce cell death or senescence in tumors while sparing normal cells. This approach seeks to develop new therapeutic strategies that could improve the effectiveness of cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with aggressive or metastatic cancers who have not responded well to existing treatments.
Not a fit: Patients with early-stage cancers or those whose tumors do not involve CDK1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that specifically target cancer cells while minimizing harm to normal cells.
How similar studies have performed: Previous research has shown promise in targeting other cyclin-dependent kinases, suggesting that this approach could yield significant advancements in cancer treatment.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOGA, ANDREI — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: GOGA, ANDREI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy